Neuroscience

Articles and news from the latest research reports.

64 notes

Stem cell materials could boost research into key diseases
Stem cell manufacturing for drug screening and treatments for diseases such as Huntington’s and Parkinson’s could be boosted by a new method of generating stem cells, a study suggests.
Scientists have developed a family of compounds that can support the growth of human embryonic stem cells on a large scale for use in drug testing or treatments.
The new materials, which are water-based gels, act as a tiny scaffold to which cells can cling as they grow. Normally cells must be grown on expensive biological surfaces that can carry pathogens and contaminate cells.
Once cells have multiplied sufficiently for their intended purpose, the gels can be cooled, enabling the stem cells to drop off the scaffold without becoming damaged.
The new approach surpasses existing techniques of separating cells by mechanical or chemical means, which carry a greater risk of damage to cells.
Scientists say the materials could offer a means of enabling the stem cells to be produced in large numbers efficiently and without the risk of inadvertent contamination, facilitating research, drug screening programmes and clinical applications that call for large numbers of cells.
Researchers at the University of Edinburgh developed the new materials by screening hundreds of potential compounds for their ability to support stem cell growth. From a shortlist of four, one has been found to be effective, and researchers say the remaining three show similar potential.
Stem cells provide a powerful tool for screening drugs as they can be used to show the effects of drugs on cells and systems within the body.
The study, published in Nature Communications, was supported by the European Union Framework 7 Grant Funding. The gels are being developed under licence by technology company Ilika.
Dr Paul de Sousa, of the University of Edinburgh’s Scottish Centre for Regenerative Medicine, said: “This development could greatly enhance automated production of embryonic stem cells, which would improve the efficiency and reduce the cost of stem cell manufacturing. We are also looking into whether this work could help develop pluripotent stem cells induced from adult cells.”

Stem cell materials could boost research into key diseases

Stem cell manufacturing for drug screening and treatments for diseases such as Huntington’s and Parkinson’s could be boosted by a new method of generating stem cells, a study suggests.

Scientists have developed a family of compounds that can support the growth of human embryonic stem cells on a large scale for use in drug testing or treatments.

The new materials, which are water-based gels, act as a tiny scaffold to which cells can cling as they grow. Normally cells must be grown on expensive biological surfaces that can carry pathogens and contaminate cells.

Once cells have multiplied sufficiently for their intended purpose, the gels can be cooled, enabling the stem cells to drop off the scaffold without becoming damaged.

The new approach surpasses existing techniques of separating cells by mechanical or chemical means, which carry a greater risk of damage to cells.

Scientists say the materials could offer a means of enabling the stem cells to be produced in large numbers efficiently and without the risk of inadvertent contamination, facilitating research, drug screening programmes and clinical applications that call for large numbers of cells.

Researchers at the University of Edinburgh developed the new materials by screening hundreds of potential compounds for their ability to support stem cell growth. From a shortlist of four, one has been found to be effective, and researchers say the remaining three show similar potential.

Stem cells provide a powerful tool for screening drugs as they can be used to show the effects of drugs on cells and systems within the body.

The study, published in Nature Communications, was supported by the European Union Framework 7 Grant Funding. The gels are being developed under licence by technology company Ilika.

Dr Paul de Sousa, of the University of Edinburgh’s Scottish Centre for Regenerative Medicine, said: “This development could greatly enhance automated production of embryonic stem cells, which would improve the efficiency and reduce the cost of stem cell manufacturing. We are also looking into whether this work could help develop pluripotent stem cells induced from adult cells.”

Filed under neurodegerative disorders stem cells embryonic stem cells drug screening medicine science

  1. hiddenprince44 reblogged this from neurosciencestuff
  2. mizukitsune10 reblogged this from ashynarr
  3. ashynarr reblogged this from neurosciencestuff
  4. alloftime reblogged this from neurosciencestuff
  5. hemaris-diffinis reblogged this from neurosciencestuff
  6. brattydee reblogged this from neurosciencestuff
  7. reikarabbit reblogged this from neurosciencestuff
  8. theworldaccordingtoevie reblogged this from neurosciencestuff
  9. uncloudedillusions reblogged this from neurosciencestuff
  10. neon0561 reblogged this from neurosciencestuff
  11. nerupe reblogged this from neurosciencestuff
  12. theyallgotkilled reblogged this from culturerevo
  13. ilackthebeautyyoudisplay reblogged this from culturerevo
  14. alchemistofpossibility reblogged this from smileyani
  15. smileyani reblogged this from neurosciencestuff
  16. sirlowkey reblogged this from neurosciencestuff
  17. spazzyrainbowfishlover reblogged this from neurosciencestuff
  18. ahandsomestark reblogged this from neurosciencestuff
  19. ourbravenewworld reblogged this from neurosciencestuff
free counters